Our CEO Dr. Joan Feixas will be attending the Future Cannabis Strategies Europe 2020, taking place in Royal Lancaster London on the 29^th and 30^th of January, 2020.

During the event, we will be discussing with key partners and customers about our Cannabinoids Cocrystal Platform, which enables the manufacturing of a wide range of cannabinoids, both from natural and synthetic origin.

As part of this platform, Enantia is already developing commercial batches of API grade cGMP Cannabidiol (CBD), along with minor cannabinoids such as Cannabidivarin (CBDV), Cannabigerol (CBG), Cannabichromene (CBC) and Cannabinol (CBN).

If you are interested in our very high-quality cannabinoids, or if you are looking for a cost-effective purification technology for your cannabis extracts, do not hesitate to contact us to organize a meeting.